Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
Top Cited Papers
- 11 February 2011
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 22 (5), 1071-1077
- https://doi.org/10.1093/annonc/mdr006
Abstract
Background: The association between human papillomavirus (HPV) and overall survival (OS) in oropharynx cancer (OPC) was retrospectively examined in TAX 324, a phase III trial of sequential therapy for locally advanced head and neck cancer. Methods: Accrual for TAX 324 was completed in 2003 and data updated through 2008. Pretherapy tumor biopsies were studied by PCR for human papillomavirus type 16 and linked to OS, progression-free survival (PFS) and demographics. Results: Of 264 patients with OPC, 111 (42%) had evaluable biopsies; 56 (50%) were HPV+ and 55 (50%) were HPV−. HPV+ patients were significantly younger (54 versus 58 years, P = 0.02), had T1/T2 primary cancers (49% versus 20%, P = 0.001), and had a performance status of zero (77% versus 49%, P = 0.003). OS and PFS were better for HPV+ patients (OS, hazard ratio = 0.20, P < 0.0001). Local–regional failure was less in HPV+ patients (13% versus 42%, P = 0.0006); at 5 years, 82% of HPV+ patients were alive compared with 35% of HPV− patients (P < 0.0001). Conclusions: HPV+ OPC has a different biology compared with HPV− OPC; 5-year OS, PFS, and local–regional control are unprecedented. These results support the possibility of selectively reducing therapy and long-term morbidity in HPV+ OPC while preserving survival and approaching HPV− disease with more aggressive treatment.This publication has 26 references indexed in Scilit:
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trialThe Lancet Oncology, 2011
- Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer PatientsCancer Prevention Research, 2009
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI Journal of the National Cancer Institute, 2008
- Lack of Association of Alcohol and Tobacco with HPV16-Associated Head and Neck CancerJNCI Journal of the National Cancer Institute, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Human papillomavirus 16 and head and neck squamous cell carcinomaInternational Journal of Cancer, 2007
- High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell CarcinomaJournal of Clinical Oncology, 2006
- Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable PrognosisJournal of Clinical Oncology, 2006
- Human papillomavirus type 16 and squamous cell carcinoma of the head and neck.2002
- Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx CarcinomaJNCI Journal of the National Cancer Institute, 1999